4-(1H-吡唑)-吡啶 | 19959-71-8

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 4-(1H-吡唑)-吡啶
• 英文名称: 4-(1H-pyrazol-4-yl)pyridine
• CAS: 19959-71-8
• 化学式: C₈H₇N₃
• mdl: MFCD00480339
• 分子量: 145.164
• InChiKey: TZDKFMFJVGNYLS-UHFFFAOYSA-N

物化性质

• 熔点：
  195-198°C

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H320,H335

制备方法与用途

应用

4-(1H-吡唑-4-基)吡啶可以作为有机合成中间体和医药中间体，主要应用于实验室研发及化工医药的生产过程。

反应信息

• 作为反应物：
  描述：

  4-(1H-吡唑)-吡啶 在 盐酸 、 正丁基锂 、 caesium carbonate 、 对甲苯磺酸 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.5h， 生成 tert-butyl (S)-3-(3-iodo-4-(pyridin-4-yl)-1H-pyrazol-1-yl)-pyrrolidine-1-carboxylate
  参考文献：
  名称：

  针对 EGFR Exon20 插入突变的强效、有效和选择性抑制剂的发现和优化

  摘要：

  在此，我们报告了一系列有效的 EGFR Exon20 插入抑制剂的鉴定和优化，与野生型 EGFR 相比具有显着的选择性。战略性设计的 HTS 活动、基于结构的药物设计 (SBDD) 的多次迭代和战术接头替换导致了一系列有效的野生型选择性分子，并最终发现了36 。化合物36是 EGFR Exon20 插入的有效选择性抑制剂，在 NSCLC EGFR CRISPR 工程改造的 H2073 异种移植物（携带 SVD Exon20 插入）中表现出令人鼓舞的功效，与 CLN-081 相比，在 H2073 野生型 EGFR 异种移植模型中功效降低（ 5 ），表明36可能具有较低的 EGFR 野生型相关毒性。

  DOI：

  10.1021/acs.jmedchem.4c00227
• 作为产物：
  描述：

  吡啶-4-乙酸 在 hydrazine hydrate 、 sodium hydroxide 、 三氯氧磷 作用下， 以 水 为溶剂， 反应 5.25h， 生成 4-(1H-吡唑)-吡啶
  参考文献：
  名称：

  Design, synthesis, and biologic evaluation of some novel N-arylpyrazole derivatives as cytotoxic agents

  摘要：

  A novel series of N-arylpyrazole derivatives (5a-5d, 7a-7c) has been designed and synthesized via aromatic substitution reaction of N-nonsubstituted pyrazoles with 4-fluoronitrobenzene in the presence of base. The structures of these compounds were established on the basis of elemental (C, H, and N) and spectral analysis (H-1 NMR, C-13 NMR, HRMS, and FT-IR). All the compounds were tested for their cytotoxic activity in vitro against four human tumor cell lines: carcinoma (Bel-7402), nasopharyngeal carcinoma (KB), immature granulocyte leukemia (HL-60), and gastrocarcinoma (BGC-823) by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. The results showed that most of the obtained compounds exhibited promising cytotoxicity against tested carcinoma cell lines with low IC50 values. The bis-pyrazole derivative 7c, bearing alkoxy group on the 5-position of phenyl ring, was the most effective one. It is inhibition of cell growth of Bel-7402 cells was 1.5-fold higher than that found for cisplatin. And, also mono-pyrazole derivatives 5a and 5b, decorated with trifluoromethyl group on the phenyl ring, displayed better cytotoxicity than that of cisplatin against Bel-7402 cell line.

  DOI：

  10.1007/s00044-013-0552-1

文献信息

• BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS
  申请人：Singh Jasbir

  公开号：US20090136473A1

  公开（公告）日：2009-05-28

  The present invention relates to a genus of biaryl compounds containing at least one further ring. The compounds are PDE4 inhibitors useful for the treatment and prevention of stroke, myocardial infarct and cardiovascular inflammatory diseases and disorders. The compounds have general formula Ia, Ib, Ic or Id: A particular embodiment is

  本发明涉及一类含有至少一个进一步环的联苯化合物的属。这些化合物是PDE4抑制剂，用于治疗和预防中风、心肌梗死和心血管炎症性疾病和紊乱。这些化合物具有一般式Ia、Ib、Ic或Id： 一个特定的实施例是
• [EN] COPPER (I) PYRAZOLATE DIMERS FOR ELECTROLUMINESCENT DEVICES<br/>[FR] DIMÈRES DE PYRAZOLATE DE CUIVRE (I) POUR DES DISPOSITIFS ÉLECTROLUMINESCENTS
  申请人：DOW GLOBAL TECHNOLOGIES LLC

  公开号：WO2016057441A1

  公开（公告）日：2016-04-14

  The invention provides compositions comprising copper(I) pyrazolate dimer compounds for use in OLEDs applications. The inventive compositions can be used to generate visible light colors or a color blend in electronic devices.

  该发明提供了含有铜(I)吡唑二聚体化合物的组合物，用于OLED应用。这些创新的组合物可用于在电子设备中产生可见光颜色或颜色混合。
• 질소를 포함하는 헤테로고리로 치환된 축합 피리미딘 유도체 및 그의 의약 용도
  申请人：ILDONG PHARMACEUTICAL CO., LTD. 일동제약(주)(120160670930) Corp. No ▼ 110111-6139277BRN ▼803-88-00431

  公开号：KR20210076693A

  公开（公告）日：2021-06-24

  본 출원은 질소를 포함하는 헤테로고리로 치환된 축합 피리미딘 유도체 및 그의 의약 용도에 관한 것으로서, 하기의 화학식 I로 표시되는 화합물, 용매화물, 입체 이성질체 또는 이들의 약학적으로 허용가능한 염, 및 이를 포함하는 암의 예방 또는 치료용 약제학적 조성물을 제공한다: [화학식 I] .

  这个申请涉及一种含氮杂环取代的嘧啶衍生物及其药用用途，提供了如下化合物，溶剂化合物，立体异构体或其药学上可接受的盐，以及包含它们的用于预防或治疗癌症的药学组合物：[化学式 I]。
• [EN] INDOLIN-2-ONE AND 1,3-DIHYDRO-PYRROLO[3,2-c]PYRIDIN-2-ONE DERIVATIVES<br/>[FR] DÉRIVÉS D'INDOLIN-2-ONE ET DE 1,3-DIHYDRO-PYRROLO[3,2-C]PYRIDIN-2-ONE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015177110A1

  公开（公告）日：2015-11-26

  The present invention is concerned with indolin-2-one and l,3-dihydro-pyrrolo[3,2-c]pyridin-2-one derivatives of general formula (I) wherein Ar1 is phenyl, pyridinyl or pyrimidinyl; Ar2 is a 5 or 6 membered heteroaryl group, containing 2 or 3 heteroatoms, selected from N, O or S; R1 is hydrogen, lower alkyl, halogen or lower alkoxy; R2 is hydrogen or lower alkyl; R3 is hydrogen, lower alkyl, lower alkyl substituted by hydroxy, cycloalkyl, oxetan-3-yl, pyridinyl, imidazolyl, pyrazolyl, pyrimidinyl, which rings may optionally substituted by lower alkyl, or is -(CH2)3-S(O)2-cyclopropyl; X is CH or N; n is 1 or 2; as well as with a pharmaceutically acceptable salts thereof, with a racemic mixture, or with its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof, for use in the treatment of certain central nervous system disorders which are positive (psychosis) and negative symptoms of schizophrenia, substance abuse, alcohol and drug addiction, obsessive-compulsive disorders, cognitive impairment, bipolar disorders, mood disorders, major depression, treatment resistant depression, anxiety disorders, Alzheimer's disease, autism, Parkinson's disease, chronic pain, borderline personality disorder, sleep disturbances, chronic fatigue syndrome, stiffness, antiinflammatory effects in arthritis and balance problems.

  本发明涉及一般式(I)的吲哚啉-2-酮和1,3-二氢吡咯并[3,2-c]吡啶-2-酮衍生物，其中Ar1是苯基、吡啶基或嘧啶基；Ar2是含有2个或3个N、O或S杂原子的5或6元杂芳基团；R1是氢、低碳基、卤素或低烷氧基；R2是氢或低碳基；R3是氢、低碳基、低碳基取代的羟基、环烷基、氧杂环丙烯基、吡啶基、咪唑基、吡唑基、嘧啶基，这些环可能被低碳基取代，或者是-(CH2)3-S(O)2-环丙基；X是CH或N；n为1或2；以及其药学上可接受的盐、消旋混合物、对映体和/或光学异构体和/或立体异构体，用于治疗某些中枢神经系统疾病，包括精神病（正性症状和负性症状）、精神分裂症、物质滥用、酒精和药物成瘾、强迫症、认知障碍、双相情感障碍、情绪障碍、重度抑郁症、治疗难治性抑郁症、焦虑症、阿尔茨海默病、自闭症、帕金森病、慢性疼痛、边缘性人格障碍、睡眠障碍、慢性疲劳综合征、僵硬、关节炎中的抗炎作用和平衡问题。
• Thiazolyl urea compounds and methods of uses
  申请人：——

  公开号：US20020193405A1

  公开（公告）日：2002-12-19

  Selected novel urea compounds are effective for prophylaxis and treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stoke, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  选定的新型尿素化合物对预防和治疗疾病有效，如细胞增殖或凋亡介导的疾病。该发明涵盖了新型化合物、类似物、前药和其药用可接受的盐，以及用于预防和治疗中风、癌症等疾病和其他疾病或病况的药物组合物和方法。该发明还涉及制备此类化合物的方法，以及在这些过程中有用的中间体。